IRTC (48) PLSE (41) NVST (49) HTFL (53) ⌘ Pro Terminal →

ICU Medical Inc. (ICUI) — RQD Stock Rating Cockpit

$168.65 +1.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $168.74

ICU Medical Inc. (ICUI) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $4.22B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $168.73 (+0.05%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICUI)Realized 20D OHLCV Swing Band: ±6.5%

Deterministic 5-Pillar Attribution (55/100 Composite)

🔍 WHY ICUI SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (22% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 50.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$160.32+1.7% Next Q

Q2 (-2Q)

Grade C-$162.99+2.2% Next Q

Q3 (-1Q)

Grade C-$166.62+1.2% Next Q

Current

Grade D+$168.65-0.5% Hist 90D α

Trajectory: D (47) → D+ (55)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ICUI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, ICUI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.68% YoY Shares) — any gross margin slip below 34.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($164.22) or 200D SMA ($148.59) invalidates the momentum regime and cuts Target Base ($166.37) toward Bear Floor ($129.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICUI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICUI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 55%NO 45%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE70% OF RANGE

L: $113$168.65H: $193

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ICUI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

1.0% ROIC with 36.8% gross margin and 2.18% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (75)

Altman-Z 4.20 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (52)

19/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like ICUI

✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICUI)

✓Walkthrough of ICUI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICUI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.48%▲ ASCENDING CHANNEL

2026-10-30O $169.6H $170.0L $163.2C $168.7VOL 216.6K

RES: $225.8SUP: $158.1SMA50: $164.2SMA200: $148.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICUI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICUI Butterfly Map → + Track ICUI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

40.6%/yr Implied 5Y Growth

vs. -6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICUI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICUI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICUI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICUI)

Health Care Rank #278 of 1016 ⚔️ IRTC vs ICUI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICUI vs. IRTC, PLSE, NVST, HTFL)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ICU Medical Inc. (ICUI) ranks #278 by composite RQD confidence (55/100, grade D+) and #178 by equity capitalization ($4.22B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ICUI currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICUI ACTIVE ICU Medical Inc.	D+	55/100	—	36.8%	1.0%	+1.36%	$4.22B	Benchmark Subject
IRTC iRhythm Holdings Inc.	D	48/100	—	70.6%	-13.5%	+3.07%	$4.21B	/irtc-vs-icui →
PLSE Pulse Biosciences Inc	D-	41/100	—	-30.0%	-30.7%	+3.37%	$3.96B	/plse-vs-icui →
NVST Envista Holdings Corporation	D	49/100	84.1x	54.7%	5.1%	+2.80%	$3.95B	/nvst-vs-icui →
HTFL Heartflow Inc.	D+	53/100	—	76.8%	-12.0%	+2.42%	$5.26B	/htfl-vs-icui →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000883984

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ICU Medical Inc. (ICUI) reported GAAP revenue of $2.23B (-6.3% vs. FY2024 revenue of $2.38B , and -1.2% cumulative change since FY2023) , GAAP net income of $732.0K, operating cash flow of $179.8M, and free cash flow of $91.8M (-26.4% YoY). On the balance sheet, ICUI closed FY2025 with $4.05B in total assets against $1.27B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.23B	$732.0K	$179.8M	$91.8M	$4.05B	$1.27B
FY2024 (FY)	2024-12-31	$2.38B	-$117.7M	$204.0M	$124.7M	$4.20B	$1.53B
FY2023 (FY)	2023-12-31	$2.26B	-$29.7M	$166.2M	$166.2M	—	—

3. ICUI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICUI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ICU Medical Inc. (NASDAQ: ICUI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $168.65 (+1.36% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ICUI ranks #278 in composite RQD confidence.

How does ICUI compare to IRTC and PLSE in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ICUI carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 36.8%, and ROIC of 1.0%. By comparison, IRTC (iRhythm Holdings Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B) and PLSE (Pulse Biosciences Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -30.7%, cap $3.96B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICUI?

Per ICUI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883984), ICU Medical Inc. generated $2.23B in revenue (-6.3% YoY), $732.0K in net income, and $91.8M in free cash flow against $4.05B in total assets and $1.27B in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICUI trading relative to its 50-day, 200-day, and 52-week technical levels?

ICUI last traded at $168.65 (+1.36% on volume of 202,523 shares), positioning the stock +2.70% above its 50-day simple moving average ($164.22) and +13.50% above its 200-day simple moving average ($148.59). Across its 52-week range of $113.37 to $192.85, ICUI sits at the 69.6% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($157.69 to $179.61).

ICUI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ICUI stock right now?

ICU Medical Inc. (ICUI) currently earns a Roarable Rating of D+ (Sell — SELL) with 55/100 RQD Confidence. Stretched risk/reward at current multiples (1% return on capital) under elevated 10-year interest-rate pressure.

What is ICUI's 12-month price target and RQD AI Jury consensus?

ICUI's 12-month base price target is $166.37 (range $129.77 to $202.49), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ICUI RQD Cockpit ICUI 12M Forecast ICUI Earnings & Move ICUI Dividends & DRIP ICUI Insiders & 13F ICUI Whale Options ICUI Profit Sankey ICUI News & Why